Carnosine vs MGF

Dipeptide that buffers lactic acid in muscle during high-intensity exercise; chelates metal ions; prevents and reverses protein glycation; scavenges aldehyde oxidative byproducts

Carnosine is a naturally occurring dipeptide (β-alanyl-L-histidine) synthesized in skeletal muscle and other excitable tissues from β-alanine and histidine, where it functions as an intracellular pH buffer, antioxidant, and antiglycation agent that supports cellular homeostasis under metabolic stress. Its principal role in exercise physiology centers on buffering the proton accumulation associated with high-intensity anaerobic work, attenuating acidosis-driven impairment of contractile function and extending time to fatigue during supra-threshold effort. Human randomized controlled trials using β-alanine supplementation — which elevates muscle carnosine content by increasing substrate availability — have demonstrated attenuation of fatigue during repeated high-intensity exercise bouts in trained athletes, providing the primary human evidence base for carnosine's performance effects. Carnosine is available as an oral dietary supplement in many jurisdictions; the evidence base for muscle carnosine loading via oral β-alanine supplementation is established in human RCTs, while direct exogenous carnosine administration by injection remains investigational with no regulatory approval or established clinical evidence base.

Splice variant of IGF-1; acts locally at site of muscle damage to activate satellite cells (muscle stem cells) for repair and hypertrophy

Mechano growth factor (MGF), also designated IGF-1Ec, is a splice variant of the IGF-1 gene produced locally in skeletal muscle in response to mechanical loading and tissue microdamage, and is proposed to function as an autocrine/paracrine signal that activates muscle satellite cells and initiates the early repair response, a role distinct from the endocrine actions of systemic IGF-1. The unique C-terminal E-peptide domain of MGF is proposed to be the bioactive moiety responsible for satellite cell activation and progenitor cell proliferation, acting through mechanisms that are at least partially independent of IGF-1R and specific to the mechanical stress response rather than systemic growth signaling. Human muscle progenitor cell studies have demonstrated that the MGF E-peptide activates muscle progenitor cells and enhances their fusion potential across different age groups, suggesting a role in the age-related decline in muscle repair capacity. MGF is a research compound with no regulatory approval in any jurisdiction; exogenous administration is investigational, no human clinical pharmacokinetic or safety data has been established, and published evidence is limited to in vitro and preclinical contexts. MGF vs PEG-MGF: native MGF has a very short half-life in circulation, limiting its duration of action after exogenous administration. PEG-MGF (pegylated MGF) is a chemically stabilized version in which polyethylene glycol is conjugated to the peptide to extend its biological half-life — the same technology used to extend the half-life of therapeutic proteins such as PEG-EPO. Research compound suppliers often offer both forms; PEG-MGF is the more commonly studied variant in animal myopathy models for this pharmacokinetic reason. Neither form has human clinical data. MGF in muscle research: interest in MGF as a research compound centers on its proposed role in the lag phase of muscle repair following eccentric exercise-induced damage — the window when satellite cells are activated before proliferating and fusing into existing myofibers. In aged muscle, MGF expression following mechanical loading is reduced relative to young tissue, and this deficit has been proposed as a contributing factor to age-related sarcopenia in the research literature. Providers offering research peptides in the performance and recovery category are listed in the PeptideBase directory.